Otsuka's VOYXACT Shows Positive Final Phase 3 Results for IgA Nephropathy

Otsuka Pharmaceutical announced positive final two-year results from its Phase 3 VISIONARY study for VOYXACT (sibeprenlimab-szsi) in adults with primary IgA nephropathy. Published in The New England Journal of Medicine, the study demonstrated significant preservation of kidney function and a 97.1% reduction in the risk of a composite kidney outcome event compared to placebo. These landmark findings support selective APRIL inhibition as a disease-modifying treatment, offering a potential new therapy for this progressive kidney disease.